
Core Business
Biopharma CDMO Services
Mycenax Biotech Inc.
Mycenax (Stock code: 4726.TW) is a CDMO (Contract Development and Manufacturing Organization) company that provides biopharmaceutical services and solutions for drug development and production, with customers in Taiwan, Japan, Korea, Singapore, among other Asia-Pacific regions, as well as Europe and the United States.
With a basis in the production of biosimilars and new biopharmaceuticals, since 2019 Mycenax has shifted to advancing technology platforms as well as building and expanding GMP plants to meet international standards, fulfilling the diverse needs of customers and providing tailor-made and streamlined CDMO services.
Taiwan
Date | Title | |
2023-07-19 | BIO Asia–Taiwan 2023 亞洲生技大會來了!晟德集團打造台灣生技波克夏 聚焦CDMO、AI、高階醫材 立足台灣 放眼世界 | Detail |
2023-12-05 | 晟德法說》釋「長線」佳音 展望明年景氣持樂觀看法 | Detail |
2024-06-25 | 晟德股東會/承認配發1.5元現金股利 殖利率3.3% 連續24年配發股利 2024年成長充滿信心 續替股東創造最大價值 | Detail |
2024-07-19 | 林榮錦打造晟德生技投資帝國 | Detail |
2024-08-13 | 晟德(4123)Q2財報新聞稿 | Detail |
2025-03-17 | 晟德2025年 Q1法人說明會 | Detail |
2025-04-09 | 晟德與順藥同步啟動庫藏股計畫 強調對營運前景高度信心 | Detail |